Clinical Trials Logo

Epidermoid Carcinoma clinical trials

View clinical trials related to Epidermoid Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04583605 Active, not recruiting - Melanoma Clinical Trials

The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors

Start date: January 1, 2014
Phase:
Study type: Observational

In this study, we compared a negative pressure wound therapy, versus a conventional dressing in order to evaluate the most efficient wound therapy closure after axillary and inguinal lymph nodes dissections in the management of metastatic skin tumors. A vacuum assisted closure therapy should prevent these comorbidities.

NCT ID: NCT03546998 Recruiting - Achalasia Clinical Trials

Epidermoid Cancer Development in Esophageal Achalasia

Start date: January 1, 1973
Phase:
Study type: Observational [Patient Registry]

Esophageal achalasia is a precancerous condition for epidermoid carcinoma; incidence and risk factors for cancer development are not defined. Incidence and risk factors for epidermoid carcinoma development in achalasia patients were investigated.

NCT ID: NCT01581840 Completed - Clinical trials for Epidermoid Carcinoma

Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus

Start date: June 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment is based on radiochemotherapy for locally advanced tumours. The objective of treatment is to provide a cure without resorting to abdominoperineal amputation, while preserving sphincter function. The prognosis is mainly related to tumour size and lymph node invasion. The large majority of patients do not show any spread remote from the tumour at the time of diagnosis (2). Recurrences are mainly of a local/regional nature and require abdominoperineal amputation. This type of intervention is not always possible or complete, which then gives rise to the particularly distressing risk of local progression, with survival at 3 years of approximately 30% (3). It is therefore very important to achieve a complete and permanent tumour response from initial treatment with radiochemotherapy. Furthermore, the use of an anti-EGFR antibody in combination with exclusive radiotherapy in ENT cancer was able to increase recurrence-free survival and overall survival in these patients. These data are in favour of the use of a combination of chemotherapy and anti-EGFR antibodies in epidermoid cancer of the anus.